When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Última revisión: 16 Mar 2025
Última actualización: 12 Jul 2024

Resumen

Definición

Anamnesis y examen

Principales factores de diagnóstico

  • presencia de factores de riesgo
  • más de 6 semanas de duración
  • dolor en las articulaciones
  • inflamación de las articulaciones
  • fiebre

Otros factores de diagnóstico

  • edad menor a 6 años
  • rigidez matinal
  • cojera
  • movimiento limitado
  • erupción
  • entesitis
  • discrepancia en la longitud de las extremidades
  • uveítis
  • nódulos reumatoides

Factores de riesgo

  • sexo femenino
  • polimorfismo del antígeno leucocitario humano (HLA)
  • antecedentes familiares de autoinmunidad
  • la exposición a antibióticos durante la infancia

Pruebas diagnósticas

Primeras pruebas diagnósticas para solicitar

  • hemograma completo (HC)
  • velocidad de sedimentación globular
  • proteína C-reactiva
  • anticuerpos antinucleares (ANA)
  • factor reumatoide (FR)

Pruebas diagnósticas que deben considerarse

  • anticuerpo antipéptido cíclico citrulinado
  • prueba de clamidia
  • niveles de ferritina
  • ecografía de las articulaciones afectadas
  • resonancia magnética (IRM)

Algoritmo de tratamiento

Colaboradores

Autores

Jacqui Clinch, MRCP, FRCPCH

Consultant Paediatric Rheumatologist

Department of Paediatric Rheumatology

Bristol Royal Hospital for Children

Bristol

UK

Divulgaciones

JC declares that she has no competing interests.

Natasha Smallwood, MB, ChB, MRCPCH

Consultant Paediatric Medicine and Rheumatology

Department of Paediatric Rheumatology

Bristol Royal Hospital for Children

Bristol

UK

Divulgaciones

NS declares that she has no competing interests.

Agradecimientos

Dr Jacqui Clinch and Dr Natasha Smallwood would like to gratefully acknowledge Dr Ripal Shah, Dr Eve Bassett, Dr Sheila Angeles-Han, and Dr Sampath Prahalad, the previous contributors to this topic.

Divulgaciones

RS and EB declare that they have no competing interests. SAH and SP are authors of a number of references cited in this topic. SP is the recipient of research funding from the National Institute of Health and Arthritis Foundation.

Revisores por pares

Paul Rosen, MD

Clinical Director

Division of Pediatric Rheumatology

Children's Hospital of Pittsburgh

Pittsburgh

PA

Divulgaciones

PR declares that he has no competing interests.

Murray Passo, MD

Director

Division of Rheumatology

Professor of Pediatrics

Department of Pediatrics

Medical University of South Carolina

Charleston

SC

Divulgaciones

MP is an author of a number of references cited in this topic. He is a consultant to Pfizer Pharmaceuticals as the chairman of the Expert Advisory Panel to review toxicity of celecoxib. He has been a visiting professor from the American College of Rheumatology, and from the American Academy of Pediatrics.

Patricia Woo, CBE

Professor of Paediatric Rheumatology

University College London

London

UK

Divulgaciones

Not disclosed.

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad